Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Blue Sky Uranium Expands Drill Plan to Advance the Ivana Uranium-Vanadium Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Harrow Inc HROW

Healthcare Biotechnology
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America... see more

Recent & Breaking News (NDAQ:HROW)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow Health, Inc. - HROW

Newsfile February 27, 2023

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

Business Wire February 27, 2023

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

PR Newswire February 25, 2023

HARROW HEALTH SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options

PR Newswire February 25, 2023

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM

PR Newswire February 24, 2023

Harrow Health Investor Alert

Newsfile February 24, 2023

The Law Offices of Frank R. Cruz Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

Newsfile February 24, 2023

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

Business Wire February 24, 2023

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

Business Wire February 24, 2023

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile February 24, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow Health, Inc. - HROW

PR Newswire February 23, 2023

Harrow Health Shareholder Action Reminder

Newsfile February 23, 2023

The Law Offices of Frank R. Cruz Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

Business Wire February 23, 2023

Harrow Health Shareholder Action Reminder

Newsfile February 22, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire February 22, 2023

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM

Business Wire February 22, 2023

Harrow Launches Next-Generation Compounded Atropine Formulations

Business Wire February 15, 2023

Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO(TM) (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023

Business Wire February 2, 2023

Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products

Business Wire January 23, 2023

Harrow Announces Availability of Fortisite(TM) Formulations for In-Office Use

Business Wire January 5, 2023